What is the current MacroGenics market capitalization?
The current market capitalization of MacroGenics is 219.85 M USD.
MacroGenics Market capitalization 2024
MacroGenics Market capitalization
219.85 M USD
Ticker
MGNX
ISIN
US5560991094
WKN
A1W6ND
In 2024, MacroGenics's market cap stood at 219.85 M USD, a -28.94% increase from the 309.4 M USD market cap in the previous year.
The MacroGenics Market capitalization history
| YEAR | Market Capitalization (undefined USD) |
|---|---|
| 2023 | 0.37 |
| 2022 | 0.39 |
| 2021 | 1.51 |
| 2020 | 1.01 |
| 2019 | 0.7 |
| 2018 | 0.87 |
| 2017 | 0.67 |
| 2016 | 0.84 |
| 2015 | 1.02 |
| 2014 | 0.7 |
| 2013 | 0.63 |
| 2012 | - |
| 2011 | - |
MacroGenics Aktienanalyse
What does MacroGenics do?
MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby elicit a targeted response. The company relies on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, allowing for the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by curing or at least managing severe diseases. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody manufacturing (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used to identify new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is highly effective for tumor treatment in the solid area. Autoimmune research and development MacroGenics is a leading developer of Neuromyelitis Optica Spectrum Disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in this field. Polyclonals and biosimilars This area includes the production of antibody polypeptides and biosimilar drugs. Antibody polypeptides can be used to treat infectious diseases or diagnose diseases. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic replicas. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and is constantly working to expand its product pipelines. The company employs over 400 employees and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products for the treatment of cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue growing in the coming years and harness its innovative power to further benefit patients. MacroGenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring MacroGenics's Market Capitalization
MacroGenics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of MacroGenics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
MacroGenics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in MacroGenics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about MacroGenics stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like MacroGenics.
How has the market capitalization of MacroGenics developed in recent years?
The market capitalization of MacroGenics has increased/decreased by -28.94% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of MacroGenics?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of MacroGenics?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of MacroGenics have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does MacroGenics pay?
Over the past 12 months, MacroGenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MacroGenics is expected to pay a dividend of 0 USD.
What is the dividend yield of MacroGenics?
The current dividend yield of MacroGenics is .
When does MacroGenics pay dividends?
MacroGenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MacroGenics?
MacroGenics paid dividends every year for the past 0 years.
What is the dividend of MacroGenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MacroGenics located?
MacroGenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von MacroGenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MacroGenics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did MacroGenics pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of MacroGenics in the year 2023?
In the year 2023, MacroGenics distributed 0 USD as dividends.
In which currency does MacroGenics pay out the dividend?
The dividends of MacroGenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MacroGenics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MacroGenics
Our stock analysis for MacroGenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MacroGenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
